Alector Discontinues Phase 2 Trial of Nivisnebart for Early Alzheimer's Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy ALEC?
Alector (ALEC) confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer's disease will be discontinued. The decision follows a pre-specified futility analysis conducted by an IDMC, which concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression at completion. "This outcome is disappointing for patients and families affected by Alzheimer's disease and underscores the complexity of developing effective treatments for this devastating disease," said Arnon Rosenthal, CEO of Alector. "We are deeply grateful to the patients, caregivers, investigators and study staff who participated in the PROGRESS-AD trial and contributed to advancing the scientific understanding of progranulin biology in neurodegeneration. We remain committed to progressing our broader pipeline of programs targeting neurodegenerative disease, including multiple wholly owned candidates enabled by our ABC platform." Alector and GSK (GSK) have been co-developing nivisnebart. The companies will work closely with study investigators to inform participants enrolled in the PROGRESS-AD trial. Full results will be shared at a future medical meeting or congress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALEC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALEC
Wall Street analysts forecast ALEC stock price to fall
8 Analyst Rating
1 Buy
5 Hold
2 Sell
Hold
Current: 2.440
Low
0.90
Averages
2.10
High
5.00
Current: 2.440
Low
0.90
Averages
2.10
High
5.00
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alector Discontinues Mid-Stage Alzheimer’s Trial for Latozinemab
- Trial Discontinuation: Alector announced the discontinuation of its mid-stage trial for latozinemab after recommendations from its independent data monitoring committee, indicating that the 76-week global study was unlikely to meet its primary endpoint of slowing disease progression, resulting in a ~5% rise in stock price.
- Partnership Impact: The PROGRESS-AD trial was a key component of Alector's collaboration with GSK, and its discontinuation highlights the challenges faced by Alector following last year's Phase 3 trial failure for another form of dementia, raising concerns about the viability of their pipeline.
- Commitment to Future Development: Despite the trial's halt, CEO Arnon Rosenthal emphasized Alector's commitment to advancing its broader pipeline targeting neurodegenerative diseases, including multiple wholly owned candidates enabled by their ABC platform, showcasing confidence in future research endeavors.
- Market Reaction Analysis: Alector's stock price increase following the trial discontinuation reflects investor trust in the company's other research projects, indicating that despite setbacks, the market remains optimistic about its potential in the neuroscience field.
See More
Middle East Stock Markets: Small-Cap Gems Analysis
- Market Performance: In April 2026, Middle Eastern stock markets exhibit cautious optimism, with most Gulf markets closing higher despite uncertainties in U.S.-Iran relations, indicating a rising interest among investors in small-cap stocks.
- Small-Cap Potential: The small-cap sector is fertile ground for discovering potential gems, driven by strong local fundamentals and strategic national initiatives, particularly in countries like the UAE and Saudi Arabia.
- ALEC Holdings Performance: ALEC Holdings PJSC has achieved an impressive 89.3% earnings growth over the past year, significantly outpacing the industry average of 18.2%, with 2025 sales reaching AED 12.60 billion, reflecting robust financial health.
- YAMAMA Cement Developments: YAMAMA Cement Company has increased its clinker output by 25%, now producing 12,500 tons daily, with earnings growing to SAR 482.88 million for 2025, showcasing its competitive edge and value potential in the market.
See More
Alector Upgraded to Overweight by Cantor Fitzgerald on BBB Technology Potential
- Platform Potential: Cantor Fitzgerald upgraded Alector (ALEC) from Neutral to Overweight, highlighting the significant potential value of its blood-brain barrier technology platform (ABC), which could position the company as a major player in the neurodegenerative disease space.
- Resource Reallocation: Following discussions with Alector executives, the company decided to prioritize resources towards the ABC platform to support the delivery of brain-targeting therapies, reflecting its commitment to this technology.
- Positive Market Reaction: Alector's shares rose after the upgrade, indicating investor confidence in its BBB-crossing technology, although the current market does not fully reflect the value of the ABC platform.
- Future Outlook: Analysts noted that the potential of Alector's ABC platform in neurodegenerative drug development is not yet fully recognized by the market, suggesting significant business growth opportunities ahead.
See More
Alector Shares Surge 15% After Upgrade to Buy by BRIG
- Upgrade Impact: Alector shares rose approximately 15% following BRIG's upgrade from Neutral to Buy, indicating positive market sentiment towards the company's strategic pivot towards its blood-brain barrier technology platform.
- Strategic Shift: After a late-stage trial setback for the dementia treatment latozinemab developed with GSK, Alector announced a resource reallocation to its BBB technology platform, Alector Brain Carrier, reflecting a reassessment of its future therapeutic strategies.
- Workforce Reduction and Project Adjustments: The failure of the INFRONT-3 clinical trial forced Alector to cut nearly 49% of its workforce and halt the open-label extension of INFRONT-3 and the continuation study for latozinemab, which, while impacting operations in the short term, allows for a focused approach moving forward.
- Analyst Optimism: BTIG analyst Thomas Shrader noted that Alector's new direction alleviates concerns following the FTD trial failure, setting a new price target of $6 per share, suggesting a bullish outlook on the company's future developments.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
Alector Discontinues Mid-Stage Alzheimer’s Trial for Latozinemab
- Trial Discontinuation: Alector announced the discontinuation of its mid-stage trial for latozinemab after recommendations from its independent data monitoring committee, indicating that the 76-week global study was unlikely to meet its primary endpoint of slowing disease progression, resulting in a ~5% rise in stock price.
- Partnership Impact: The PROGRESS-AD trial was a key component of Alector's collaboration with GSK, and its discontinuation highlights the challenges faced by Alector following last year's Phase 3 trial failure for another form of dementia, raising concerns about the viability of their pipeline.
- Commitment to Future Development: Despite the trial's halt, CEO Arnon Rosenthal emphasized Alector's commitment to advancing its broader pipeline targeting neurodegenerative diseases, including multiple wholly owned candidates enabled by their ABC platform, showcasing confidence in future research endeavors.
- Market Reaction Analysis: Alector's stock price increase following the trial discontinuation reflects investor trust in the company's other research projects, indicating that despite setbacks, the market remains optimistic about its potential in the neuroscience field.
See More
Middle East Stock Markets: Small-Cap Gems Analysis
- Market Performance: In April 2026, Middle Eastern stock markets exhibit cautious optimism, with most Gulf markets closing higher despite uncertainties in U.S.-Iran relations, indicating a rising interest among investors in small-cap stocks.
- Small-Cap Potential: The small-cap sector is fertile ground for discovering potential gems, driven by strong local fundamentals and strategic national initiatives, particularly in countries like the UAE and Saudi Arabia.
- ALEC Holdings Performance: ALEC Holdings PJSC has achieved an impressive 89.3% earnings growth over the past year, significantly outpacing the industry average of 18.2%, with 2025 sales reaching AED 12.60 billion, reflecting robust financial health.
- YAMAMA Cement Developments: YAMAMA Cement Company has increased its clinker output by 25%, now producing 12,500 tons daily, with earnings growing to SAR 482.88 million for 2025, showcasing its competitive edge and value potential in the market.
See More
Alector Upgraded to Overweight by Cantor Fitzgerald on BBB Technology Potential
- Platform Potential: Cantor Fitzgerald upgraded Alector (ALEC) from Neutral to Overweight, highlighting the significant potential value of its blood-brain barrier technology platform (ABC), which could position the company as a major player in the neurodegenerative disease space.
- Resource Reallocation: Following discussions with Alector executives, the company decided to prioritize resources towards the ABC platform to support the delivery of brain-targeting therapies, reflecting its commitment to this technology.
- Positive Market Reaction: Alector's shares rose after the upgrade, indicating investor confidence in its BBB-crossing technology, although the current market does not fully reflect the value of the ABC platform.
- Future Outlook: Analysts noted that the potential of Alector's ABC platform in neurodegenerative drug development is not yet fully recognized by the market, suggesting significant business growth opportunities ahead.
See More
Alector Shares Surge 15% After Upgrade to Buy by BRIG
- Upgrade Impact: Alector shares rose approximately 15% following BRIG's upgrade from Neutral to Buy, indicating positive market sentiment towards the company's strategic pivot towards its blood-brain barrier technology platform.
- Strategic Shift: After a late-stage trial setback for the dementia treatment latozinemab developed with GSK, Alector announced a resource reallocation to its BBB technology platform, Alector Brain Carrier, reflecting a reassessment of its future therapeutic strategies.
- Workforce Reduction and Project Adjustments: The failure of the INFRONT-3 clinical trial forced Alector to cut nearly 49% of its workforce and halt the open-label extension of INFRONT-3 and the continuation study for latozinemab, which, while impacting operations in the short term, allows for a focused approach moving forward.
- Analyst Optimism: BTIG analyst Thomas Shrader noted that Alector's new direction alleviates concerns following the FTD trial failure, setting a new price target of $6 per share, suggesting a bullish outlook on the company's future developments.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
